X4 Pharmaceuticals Statistics
Want to see XFOR full AI Analyst Report?
X4 Pharmaceuticals (XFOR) Stock Statistics & Valuation Metrics
Total Valuation
X4 Pharmaceuticals has a market cap or net worth of $324.72M. The enterprise value is $255.74M.
- Market Cap
- $324.72M
- Enterprise Value
- $255.74M
Share Statistics
X4 Pharmaceuticals has 102,113,556 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 102,113,556
- Owned by Insiders
- 0.76%
- Owned by Institutions
- 25.27%
Financial Efficiency
X4 Pharmaceuticals’s return on equity (ROE) is -0.43 and return on invested capital (ROIC) is -32.70%.
- Return on Equity (ROE)
- -0.43
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -32.70%
- Return on Capital Employed (ROCE)
- -0.33
- Revenue Per Employee
- 780.29K
- Profits Per Employee
- -1.76M
- Employee Count
- 45
- Asset Turnover
- 0.12
- Inventory Turnover
- 1.40
Valuation Ratios
The current PE Ratio of X4 Pharmaceuticals is -4.97. X4 Pharmaceuticals’s PEG ratio is -0.02.
- PE Ratio
- -4.97
- PS Ratio
- 19.47
- PB Ratio
- 3.03
- Price to FCF
- -3.45
- Price to Operating Cash Flow
- -5.54
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, X4 Pharmaceuticals had revenue of 35.11M and earned -79.20M in profits. Earnings per share was -1.87.
- Revenue
- 35.11M
- Gross Profit
- 28.86M
- Operating Income
- -86.88M
- Pretax Income
- -79.16M
- Net Income
- -79.20M
- EBITDA
- -69.00M
- Earnings Per Share (EPS)
- -1.87
Cash Flow
In the last 12 months, operating cash flow was -76.10M and capital expenditures -19.60M, giving a free cash flow of -95.70M billion.
- Operating Cash Flow
- -76.10M
- Free Cash Flow
- -95.70M
- Free Cash Flow per Share
- -0.76
Dividends & Yields
X4 Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -28.99%
- Earnings Yield
- -19.11%
Stock Price Statistics
- Beta
- 1.24
- 52-Week Price Change
- -9.27%
- 50-Day Moving Average
- 3.23
- 200-Day Moving Average
- 3.79
- Relative Strength Index (RSI)
- 51.30
- Average Volume (3m)
- 853.03K
Important Dates
X4 Pharmaceuticals upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
X4 Pharmaceuticals as a current ratio of 10.16, with Debt / Equity ratio of 41.49%
- Current Ratio
- 10.16
- Quick Ratio
- 9.98
- Debt to Market Cap
- 0.45
- Net Debt to EBITDA
- 2.03
- Interest Coverage Ratio
- -9.79
Taxes
In the past 12 months, X4 Pharmaceuticals has paid 41.00K in taxes.
- Income Tax
- 41.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
X4 Pharmaceuticals EV to EBITDA ratio is -3.16, with an EV/FCF ratio of -2.32.
- EV to Sales
- 13.06
- EV to EBITDA
- -3.16
- EV to Free Cash Flow
- -2.32
- EV to Operating Cash Flow
- -2.91
Balance Sheet
X4 Pharmaceuticals has $187.70M in cash and marketable securities with $77.20M in debt, giving a net cash position of $110.50M billion.
- Cash & Marketable Securities
- $187.70M
- Total Debt
- $77.20M
- Net Cash
- $110.50M
- Net Cash Per Share
- $1.08
- Tangible Book Value Per Share
- $0.86
Margins
Gross margin is 81.63%, with operating margin of -473.95%, and net profit margin of -474.74%.
- Gross Margin
- 81.63%
- Operating Margin
- -473.95%
- Pretax Margin
- -474.71%
- Net Profit Margin
- -474.74%
- EBITDA Margin
- -413.09%
- EBIT Margin
- -423.55%
Analyst Forecast
The average price target for X4 Pharmaceuticals is $11.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $11.25
- Price Target Upside
- 253.77% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- -50.08%
- EPS Growth Forecast
- 93.36%
Scores
- Smart Score
- 7
- AI Score
- 49
